Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Cerilliant
Queensland Health
Boehringer Ingelheim
Merck
Deloitte
Chinese Patent Office
Daiichi Sankyo
Healthtrust

Generated: December 10, 2018

DrugPatentWatch Database Preview

OXTELLAR XR Drug Profile

« Back to Dashboard

When do Oxtellar Xr patents expire, and what generic alternatives are available?

Oxtellar Xr is a drug marketed by Supernus Pharms and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has fourteen patent family members in ten countries.

The generic ingredient in OXTELLAR XR is oxcarbazepine. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the oxcarbazepine profile page.

US Patents and Regulatory Information for OXTELLAR XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-003 Oct 19, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-003 Oct 19, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-002 Oct 19, 2012 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for OXTELLAR XR
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablets 150 mg and 300 mg ➤ Subscribe ➤ Sign Up

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Harvard Business School
QuintilesIMS
Cipla
Queensland Health
Boehringer Ingelheim
Federal Trade Commission
Julphar
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.